Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Single-arm Open-label Extension Study to Assess Long-term Safety and Efficacy of Current or Prior Treatment With Denosumab in Children/Young Adults With Osteogenesis Imperfecta

NCT03638128 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03638128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03638128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Single-arm Open-label Extension Study to Assess Long-term Safety and Efficacy of Current or Prior Treatment With Denosumab in Children/Young Adults With Osteogenesis Imperfecta
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Terminated
Start date
July 26, 2018
Completion date
March 28, 2022
Enrollment
75 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

osteogenesis imperfecta (oi)